Genprex

News

Lead Researcher Behind Genprex’s Diabetes Gene Therapy Featured in New Video Interview

Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy.

Read More

Texas company licenses University of Pittsburgh gene therapy that could cure diabetes

A UPMC Children’s Hospital of Pittsburgh researcher is crediting a new, supportive environment for entrepreneurs at the University of Pittsburgh for making it possible to license a technology that may one day cure diabetes.

Read More

Genprex to Present at the 2020 LD Micro Virtual Conference

Genprex will present at the third annual LD Micro Virtual Conference on Wednesday, March 4 at 1:40 p.m. EST. Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be answering questions from investors.

Read More

The Power Behind Gene Therapy Drug Combinations

Genprex is harnessing the power of a combinational treatment approach to overcome treatment limitations and offer patients new treatment options.

Read More

Austin’s Genprex raises $25.5M with 2 stock offerings

Austin-based biotech firm Genprex is looking for more growth after raising about $25.5 million through two recent stock offerings.

Read More

Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants

The Company intends to use the net proceeds from the offering to advance its drug development programs and for working capital and general corporate purposes.

Read More

Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants

The closing of the registered direct offering is expected to take place on or about February 21, 2020, subject to the satisfaction of customary closing conditions.

Read More

Drug Candidate for Lung Cancer Receives FDA Fast Track Designation

Technology Networks spoke with Rodney Varner, CEO of Genprex, to learn more about the next steps for Oncoprex and how the FDA Fast Track Designation will facilitate the delivery of this drug to cancer patients.

Read More

UPMC Children’s Hospital Researchers Working On ‘Groundbreaking’ Procedure To Cure Diabetes

Thirty million Americans are living with diabetes and hoping someday to be cured. That day could come sooner than expected, thanks to a team of researchers at UPMC Children’s Hospital of Pittsburgh.

Read More

Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes

Genprex signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S, or 9 percent of the U.S. population.

Read More